The 2027 Global BAHM Case Competition will be held February 18-19, 2027 in Washington, D.C., with a focus on the supply chain for essential pharmaceuticals (see the summary here).

Sponsored by The HEAL Network and hosted by Johns Hopkins Carey Business School, the event offers students the opportunity to work collaboratively on a timely topic, to network with peers across the globe, to compete for cash prizes, and to meet with healthcare executives and policymakers in Washington, D.C.

In previous years, the competition has fielded teams from North America, Costa Rica, India, Kenya, and Spain who presented their business models in person or online, synchronously.

  • Gain national and international recognition for the participating programs and for the students who compete
  • Network with student and faculty peers from other select programs across the globe
  • Interact with healthcare industry professionals who serve as judges, case developers, and competition sponsors, with the primary goal of benefitting the students and their respective programs
  • Form academic-industry partnerships, identify internship/residency and future employment opportunities, and transfer knowledge from healthcare professionals to students and faculty

I learned about the [many] opportunities that Digital Health can contribute to improve the lives of the underserved. With today’s technological advancements, we can leverage the capabilities of our own smartphones to help millions of lives around the world and address issues and communities that were easily overlooked in the past.

Roni Steiner
Product Owner for the Point of Care Ultrasound Devices
MBA from IESE Business School (Class of 2021) and 2021 Case Competition participant

SEE INTERVIEWS WITH STUDENTS, JUDGES AND HOSTS FROM THE 2022 COMPETITION

Programs are invited to field their own team of 3 – 4 students. Program teams may include students from other graduate school programs within the BAHM-member school – including but not limited to MPP, MPA, MPH, MS – as long as at least one student represents an MBA program with a focus on healthcare management.

Case Overview

For a Case Summary PPT, click here

For a video introduction to the Case, click here

The U.S. pharmaceutical supply chain has a structural vulnerability at its most upstream point: the active pharmaceutical ingredients (APIs) and, further upstream, the key starting materials (KSMs) used to synthesize them. Following the August 2025 executive order directing the Department of Health and Human Services’ Administration for Strategic Preparedness and Response (HHS-ASPR) to fill the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR), HHS-ASPR has begun designating a list of essential medicines considered vital to national health and security. For most of these medicines, and for hundreds of others, China and India together account for the overwhelming majority of API and KSM production. Independent analyses built on the U.S. Pharmacopeia’s Medicine Supply Map have found China to be the sole source of at least one KSM for well over a third of all U.S.-approved APIs, with India the sole source for roughly another fifth.

As health economist Steve Parente and colleagues have argued, this dependence is no longer just a manufacturing cost story. In a May 2026 op-ed, Parente describes China as pulling ahead in the earliest, most scientifically valuable stage of drug development even as it continues to dominate downstream ingredient manufacturing. That combination changes the strategic calculus for any policy aimed at reducing dependence on Chinese and Indian supply chains: a strategy focused only on relocating manufacturing, without also strengthening the upstream science and capital base, risks winning the factory while losing the innovation. Kevin Schulman and coauthors have separately examined how concentrated, fragile healthcare supply chains translate into clinical and financial risk across the health system, and have called for a more deliberately engineered, resilient architecture spanning ingredients, manufacturing, and distribution.

In this case competition, student teams are asked to design a policy portfolio that establishes reliable access to API and KSM production for HHS-ASPR designated medicines within an accelerated 18-month horizon, using friend-shoring (allied-nation manufacturing) and onshoring (domestic U.S. manufacturing) as the two primary levers. The compressed timeline is deliberate: it forces teams to confront the real gap between what can be legislated or contracted in 18 months (e.g., redirecting volume to existing allied-nation facilities, activating stockpiles, expediting FDA site qualifications) and what genuinely cannot (e.g., permitting and building new greenfield chemical synthesis capacity from scratch). The recommended strategy should be realistic about that gap, clear about which medicines designated by HHS and ASPR can plausibly have their supply risks reduced within the window, and explicit about which longer term efforts must be initiated during that period by securing funding, selecting sites, and executing contracts.

For the detailed Case, click here

For the Case FAQ, click here

Q: Our program is based outside the U.S. How could we approach this case from a non-U.S.-centric angle?

You’re welcome to bring a non-U.S. perspective. The case is about U.S. supply security, but the solution depends on allied nations. The case names friend-shoring as one of its two main levers, and it limits friend-shoring partners to countries with FDA-recognized or compatible regulatory standards, such as the EU, Japan, South Korea and Abraham Accords signatories. A team based in one of those places may know more than a U.S. team about which facilities are underused, how long it takes to qualify a site, what local permitting involves, and how its government would negotiate. Here are a few ways to use that:

  • Design a joint or multi-country portfolio where your country is a co-investor, co-purchaser or regulatory partner rather than just a supplier.
  • Show how U.S. measures could line up with your government’s own policies on critical medicines, so allies aren’t competing for the same limited capacity.
  • Look at retaliation risk from a partner’s side. If China or India restricts exports, what happens to your country’s own drug supply when it sends volume to the U.S.?

Whatever angle you take, your plan will still be judged on whether it meets the case’s goals: less single-country dependence for HHS-ASPR designated medicines within 18 months, protected patient access, and longer-term onshoring that has actually been started. A non-U.S. perspective should help you get there, not change what the goal is.

Q: What about taking the perspective of a near-shore or friend-shore provider, or a foreign subsidiary of a U.S. company?

Yes, that’s a legitimate way in. It can make your analysis more concrete, especially on the economics of making low-margin generic ingredients outside low-cost countries. Two cautions:

  1. The deliverable is still a policy portfolio. Use the provider’s or subsidiary’s view to show which policies would actually change an investment decision: advance purchase commitments, multi-year procurement contracts, mutual recognition of inspections, tolling agreements, tariff treatment and so on. Then recommend those policies.
  2. Watch the “first mile.” Many allied-nation and near-shore API plants still buy their KSMs or intermediates from China. If you move the API step but the starting materials still come from a single source, you haven’t reduced dependence, you’ve only moved it upstream. Judges will look for supply chain mapping that goes all the way back to the KSM.

Q: Although the focus is on policy, could we develop a business plan for a pharma company trying to address the case’s objectives?

A business plan can’t replace the policy plan, but it can make it much stronger. One of the case’s objectives is a financing and governance model that attracts sustained private capital despite thin generic margins. A firm-level pro forma is one of the best ways to show your policies would actually do that.

A useful approach is to treat the business case as a stress test of your portfolio. Show a representative API or KSM investment (returns, payback, break-even volume) with and without the policies you propose. For example, compare a no-policy baseline with a version that adds an advance purchase commitment, a price floor or reliability premium in procurement, faster site qualification, and tax incentives. That shows which tools matter most and what they would cost the government.

Keep the main 10-page plan focused on the policy portfolio and put detailed financial models in the optional appendix.

Q: India is the sole source for only a fifth of U.S.-approved APIs. Couldn’t we propose moving more manufacturing from China to India?

First, a clarification on the numbers. The case cites analyses showing China is the sole source of at least one KSM for well over a third of U.S.-approved APIs, and India is the sole source for roughly another fifth. Together that’s more than half, so India is part of the concentration problem, not a way around it.

Second, the case is explicit that the goal is to eliminate single-source and dual-country (China/India) dependence. Shifting volume from China to India would still leave the U.S. dependent on a single foreign source, which doesn’t meet that goal. India also isn’t on the case’s list of example friend-shoring partners, and the case assumes India, like China, could restrict exports or retaliate within the 18-month window.

Third, much of India’s API production depends on intermediates and KSMs imported from China. Moving API work to India without moving those inputs too can leave the underlying China dependence in place.

India can still have a role. A team could argue for Indian capacity as one of several diversified sources for particular molecules, as long as it shows that the KSM supply is independent of China and explains how India fits a portfolio that doesn’t depend on any one country. A China-to-India shift as the main strategy, though, wouldn’t meet the case objectives.

Q: Should we assume all pharma companies, many of them competitors, will support the new legislation? What if they don’t?
No, you shouldn’t assume broad industry support. Working out who will support or oppose your plan is part of the assignment. Political and diplomatic feasibility is an evaluation criterion, and governance and political durability is a required section.

“Pharma” covers groups with very different interests:

  • brand-name innovator companies
  • U.S. and foreign generic manufacturers, many of which depend on low-cost China and India supply chains
  • contract manufacturers (CDMOs) and domestic API makers
  • distributors, group purchasing organizations (GPOs) and PBMs
  • hospital and pharmacy purchasers

Policies that raise input costs, such as tariffs, sourcing mandates or country-of-origin rules, may be opposed by generic firms working on thin margins, while domestic and allied manufacturers may support them. Strong submissions map these stakeholders and design around their interests. Examples include pairing requirements with incentives, phasing in obligations, offering reliability premiums in procurement, or building opt-in purchasing consortia.

Also note that the case doesn’t hand you a specific bill. You’re designing the portfolio and choosing its legal tools, whether that’s new legislation, existing executive and procurement authorities, appropriations or contracting vehicles. If any of your mechanisms ask competing companies to coordinate (for example, joint purchasing or shared capacity reservations), say how you would handle antitrust concerns.

Download the FAQ here

Students will be responsible for finding their own travel and accommodations to Washington DC and to be ready to meet on February 18 and February 19. The competition will take place at the Johns Hopkins University Bloomberg Center located at: 555 Pennsylvania Ave NW, Washington, DC 20001.

  • Teams RSVP by Friday, December 14 by completing this form.
  • Teams submit report and presentation slide deck for judges review by Friday, January 22, 2027. Please upload the materials here.
  • Teams will present their solutions to judges on the morning of Friday, February 19, 2027
  • Judges will select three finalists to present their solutions to all judges and teams in a final round the afternoon of February 19.

The competition on Friday will be held in a hybrid-format. All teams are encouraged to participate in person, and a faculty advisor from each program is invited to accompany the team. Students participating virtually will do so synchronously.

  • Team RSVP due: Friday, December 14, 2026
  • Case report due: 6:00 p.m. Washington, DC time (EST), January 22, 2027
  • Opening reception: Thursday, February 18, 6:30 p.m. EST
    • Announcement of semifinal group assignments and draw for order of semifinal presentations
  • Optional DC Health Policy Tour: February 18, 9 a.m. to 4 p.m.
    • Four site visits organized by The HEALNetwork including:
      • US Congress, Energy & Commerce Committee
      • Council of Economic Advisers, The White House
      • The World Bank (Health Unit)
      • Centers for Medicare & Medicaid Services
      • The Brookings Institution
      • Alliance for Health Policy
  • Team check-in: 7:00 a.m. EST Friday, February 19, at The Johns Hopkins University Bloomberg Center
  • Competition begins: 7:30 a.m.
  • Semi-final rounds: 7:30 a.m. – approx. 10:00 a.m., with teams divided up between two rooms. Each team has 30 minutes with the judges: a 20-minute presentation and a 10-minute Q&A. Teams will have photographs taken after their presentations.
    • Round 1 7:30 to 8:00
    • Round 2 8:05 to 8:35
    • Round 3 8:40 to 9:10
    • Round 4 9:15 to 9:45
    • Round 5 9:30-9:50 a.m.
  • Judges’ selection of finalists: 10:00 – 10:30 a.m.
  • Lunch: 11:00 a.m. – 12:00 p.m.
  • Announcement of finalists & draw for order of final presentation: 11:45 a.m. – 12:00 p.m.
  • Finalist presentations: 12:30 – 2:30 p.m.
  • Judges’ selection award winners: 2:30 – 3:00 p.m.
  • Announcement of winners and award presentation: 3:00 – 3:30 p.m.
  • Networking reception: 3:30 – 4:30 p.m.
  1. Team members may use any reference sources/materials in the public domain in conducting their research.
  2. The team deliverables must be submitted by 5:59 p.m. EST, Friday, January 22, 2027 and uploaded here. All references and data must be fully cited. The submission e-platform for these deliverables will be accessed through a tool to be determined later.  To note, all deliverables must be anonymous; they should mention neither school affiliations nor team names.
  3. The deliverables must include:
    • Written business plan (maximum 10 pages, excluding exhibits)
    • Executive summary (1 page)
    • Pitch deck (10–12 slides). Appendix slides to support Q&A responses are permitted and do not count against the presentation slide limit.
    • Optional appendix with financials, mockups, or technical architecture

Teams should ground their analysis in current supply chain and health policy research, including:

Parente, S. “China is winning the first mile of drug innovation.” Washington Examiner, May 11, 2026.

Schulman, K.A., Kumar, W., Ahuja, N., et al. “Towards resiliency in the US healthcare supply chain.” Journal of Hospital Medicine, 2025.

The White House. Executive Order, “Ensuring American Pharmaceutical Supply Chain Resilience by Filling the Strategic Active Pharmaceutical Ingredients Reserve,” August 13, 2025.

U.S. Pharmacopeia (USP). Medicine Supply Map and related Quality Matters blog series on key starting material (KSM) concentration, 2025–2026.

Council on Foreign Relations. “The Pharma Choke Point.” 2026.
Barbosu, S. and Ezell, S. “How America Can Reduce Its Dependence on Chinese Active Pharmaceutical Ingredients (APIs).” Information Technology and Innovation Foundation (ITIF), 2026.

American Medical Association, American Society of Health-System Pharmacists, American Society of Clinical Oncology, and U.S. Pharmacopeia. “Improving the Quality and Resilience of the United States Healthcare Supply Chain” (joint statement).

Each team must develop a comprehensive business plan that includes:

  1. Problem Definition and Target Population
  2. Product or Service Description (e.g., app, platform, embedded benefit)
  3. Data Strategy and Use of Price Transparency Data
  4. Consumer Engagement and Behavioral Design
  5. Revenue Model and Financial Sustainability
  6. Partnerships and Distribution Strategy
  7. Regulatory, Legal, and Ethical Considerations
  8. Growth Strategy to Reach 5 Million Consumers by 2028
  9. Risks, Limitations, and Mitigation Strategies

Scoring

  • Report, Summary, and Slide Deck: 65%
  • Presentation and question responses: 35%

Judging Criteria

  • Strategic clarity and originality
  • Feasibility and scalability of the business model
  • Effective use of medical price transparency data
  • Consumer engagement and behavioral insight
  • Financial logic and sustainability
  • Policy relevance and societal impact
  • Quality of analysis and presentation

Judges from across the global health care industry will review each submission. The top scoring teams will be awarded prizes.

  • First Place: $10,000 and the opportunity to submit a paper to Health Management, Policy and Innovation (HMPI.org)
  • Second Place: $5,000
  • Third Place: $2,500
  • Papers should be based on students’ original work. Students can work with faculty to develop their plans.
  • Not all schools can give academic credit for the competition. For those that do, requirements will be determined by the school and may take the form of independent studies, field projects, or other project-based coursework. It is up to the participating students to understand the requirements of their school at the outset of this competition.
  • AI use:
    • Competition participants may use publicly available AI tools for idea generation, literature review, and slide construction.
    • All content generated by AI must be reviewed and verified by team members for accuracy and appropriateness.
    • AI may not be used to produce full analyses or presentations without student interpretation and critical thinking.
    • Plagiarism rules apply: AI outputs that include external sources must be properly cited.
    • Only publicly available or free versions of AI tools may be used.
    • At the end of the presentation, please include an AI disclosure statement briefly explaining how AI tools were used.

©2026 Business School Alliance for Health Management

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending
or

Log in with your credentials

or    

Forgot your details?

or

Create Account